Baseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World Analysis
Open Access
- 30 April 2026
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102569
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A vision–language foundation model for precision oncologyNature, 2025
- Safety and Efficacy of 177Lu-PSMA Therapy Following 223Radium Treatment: A Retrospective Multinational Real-World AnalysisClinical Genitourinary Cancer, 2024
- Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trialeClinicalMedicine, 2024
- 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trialThe Lancet, 2024
- Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patientsScientific Reports, 2023
- Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD studyESMO Open, 2021
- [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyThe Lancet Oncology, 2018
- Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic reviewEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate CancerEuropean Urology, 2017
- Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate CancerClinical Genitourinary Cancer, 2016